Neoadjuvant plus adjuvant dabrafenib and trametinib versus adjuvant dabrafenib and trametinib in patients with stage III melanoma: a single-center retrospective cohort study
In this single-center retrospective cohort, neoadjuvant-plus-adjuvant dabrafenib and trametinib was feasible, enabling timely surgery with manageable toxicities. Survival outcomes were comparable to adjuvant-only therapy, and pathological responses in the neoadjuvant cohort provide exploratory prognostic information.
Authors
- Tao Li (ORCID: https://orcid.org/0000-0002-5924-0522)
- Dongdong Jia (ORCID: https://orcid.org/0000-0002-6804-4988)
Institutions
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1080/09546634.2025.2593214
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00